Kindler epidermolysis bullosa-like skin phenotype and downregulated basement membrane zone gene expression in poikiloderma with neutropenia and a homozygous USB1 mutation.


Journal

Matrix biology : journal of the International Society for Matrix Biology
ISSN: 1569-1802
Titre abrégé: Matrix Biol
Pays: Netherlands
ID NLM: 9432592

Informations de publication

Date de publication:
05 2021
Historique:
received: 02 04 2021
revised: 07 05 2021
accepted: 08 05 2021
pubmed: 19 5 2021
medline: 14 1 2022
entrez: 18 5 2021
Statut: ppublish

Résumé

Epidermolysis bullosa (EB) is a genotypically heterogeneous group of disorders characterized by cutaneous blistering and erosions with a tremendous spectrum of severity. One of the distinct forms of EB, Kindler EB (KEB), manifests with blistering and poikiloderma; this subtype of EB is caused by mutations in the FERMT1 gene encoding kindlin-1. In this study, we investigated a patient clinically diagnosed as KEB with reduced FERMT1 gene expression and intensity of immunostaining for kindlin-1. Transmission electron microscopy showed lamina densa reduplication, frequently observed in KEB. However, no mutations were identified in FERMT1 in this patient with consanguineous parents, and this gene resided outside of genomic regions of homozygosity (ROH). Instead, whole-exome sequencing and homozygosity mapping identified a homozygous sequence variant at the +4 position of intron 2 in the USB1 gene, encoding an exoribonuclease required for processing of U6 snRNA, a critical component of spliceosomes. Examination of the patient's RNA by RNA-Seq confirmed the pathogenicity of this variant, causing aberrant splicing predicted to result in loss of function of USB1. Mutations in this gene have been reported in patients with poikiloderma and neutropenia, with a few reported cases in association with skin fragility, a condition distinct from the KEB phenotype. Transcriptome analysis revealed that several genes, expressed in the cutaneous basement membrane zone and previously associated with different subtypes of EB, were differentially downregulated at the mRNA level. EB-associated mRNA downregulation was confirmed at protein levels by skin immunofluorescence. These observations provide a novel mechanism for blistering and erosions in the skin as a result reduced presence of adhesion complexes critical for stable association of epidermis and dermis at the level of cutaneous basement membrane zone.

Identifiants

pubmed: 34004352
pii: S0945-053X(21)00042-1
doi: 10.1016/j.matbio.2021.05.002
pii:
doi:

Substances chimiques

FERMT1 protein, human 0
Membrane Proteins 0
Neoplasm Proteins 0
Phosphoric Diester Hydrolases EC 3.1.4.-
USB1 protein, human EC 3.1.4.-

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

43-57

Subventions

Organisme : NHGRI NIH HHS
ID : U54 HG006504
Pays : United States

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None

Auteurs

Hassan Vahidnezhad (H)

Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States; Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, United States.

Leila Youssefian (L)

Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States; Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, United States.

Amir Hossein Saeidian (AH)

Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States; Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, United States; Genetics, Genomics, and Cancer Biology PhD Program, Jefferson College of Life Sciences, Thomas Jefferson University, Philadelphia, PA, United States.

Lynn M Boyden (LM)

Department of Genetics, Yale University School of Medicine, New Haven, CT 06510, United States.

Andrew Touati (A)

Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States.

Nailah Harvey (N)

Philadelphia College of Osteopathic Medicine, Philadelphia, PA, United States.

Mahtab Naji (M)

Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States; Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, United States.

Masoud Zabihi (M)

Kawsar Human Genetics Research Center, Tehran, Iran.

Mohammadreza Barzegar (M)

Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Soheila Sotoudeh (S)

Department of Dermatology, Children's Medical Center, Center of Excellence, Tehran University of Medical Sciences, Tehran, Iran.

Lu Liu (L)

Viapath, St Thomas' Hospital, London, United Kingdom.

Alyson Guy (A)

Viapath, St Thomas' Hospital, London, United Kingdom.

Ariana Kariminejad (A)

Kariminejad-Najmabadi Pathology & Genetics Center, Tehran, Iran.

Sirous Zeinali (S)

Kawsar Human Genetics Research Center, Tehran, Iran; Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.

Keith A Choate (KA)

Departments of Dermatology, Genetics, and Pathology, Yale University School of Medicine, New Haven, CT 06510, United States.

John A McGrath (JA)

St. John's Institute of Dermatology, King's College London, Guy's Campus, London, United Kingdom.

Jouni Uitto (J)

Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, United States; Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, United States. Electronic address: jouni.uitto@jefferson.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH